CytoSorbents Corp. is involved in the research, development and commercialization of medical devices with its platform blood purification technology. The Company focuses on developing this technology for multiple applications in the medical field for the treatment of  acute and chronic health complications associated with blood toxicity.

424B5 | Prospectus

Current Report (Form 8-K | Period ending 2024-12-09)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CytoSorbents (CTSO US)

424B5 | Prospectus

Current Report (Form 8-K | Period ending 2024-12-09)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-07)

Current Report (Form 8-K | Period ending 2024-10-01)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)